Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Reports from the United Kingdom have shown that the National Health Service has refused to administer the drug Kalydeco which could treat the patients with cystic fibrosis. The members of the National Health Service have voiced out that they have refused to give their patients such drugs since according to them it would be unethical to let patients be treated, only for the drug later to be withdrawn. Medical and scientific research have demonstrated that the drug Kalydeco, which has the appearance of a bluish double tablet, have the capacity to monitor the disorders of the lungs and the digestive system. Scientists have also brought up evidence showing that Kalydeco have the potential to correct the genetic fault of human beings. However, reporters have underlined that the availability of the drug on the National Health Service in England is currently being reviewed!